Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Inclusion Criteria
- STEP 1 REGISTRATION
- Patients must have histologically confirmed estrogen receptor (ER)-, progesterone receptor (PR)- and HER2-negative (triple-negative, TNBC) or ER-, PR- weakly positive and/or HER2- equivocal status and must not have received and not be planning to receive adjuvant anti-HER2 or endocrine therapies after completion of neoadjuvant chemotherapy; patients who are HER2-positive by American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines are ineligible; HER2-negative and HER2-equivocal cases as per ASCO CAP guidelines that do not receive HER2-targeted therapy are eligible; patients with weakly ER or PR positive disease, defined as ER and/or PR less than or equal to (=<) 5% by immunohistochemistry, are eligible if the treating physician considers the patient not eligible for adjuvant endocrine therapy; residual disease must be >= 1 cm in greatest dimension, and/or have positive lymph nodes (ypN1mi, ypN1, ypN2, ypN3) observed on pathologic exam * NOTE: If the ER and/or HER2 results are discordant between the initial, pre-chemotherapy, and post-chemotherapy surgical tissue, the receptor status of the residual disease has to be used to determine eligibility. Immunohistochemistry (IHC)-positive isolated tumor cells in the lymph node (N0 [i+]) are not considered node-positive and these patients also must have >= 1 cm residual invasive cancer in the breast to be eligible.
- Patients must not have metastatic disease (i.e., must be clinically M0 or Mx; systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network [NCCN] and ASCO guidelines); patients must not have locally recurrent disease
- It is preferred that axillary lymph node sampling is performed after completion of neoadjuvant chemotherapy to allow more accurate assessment of pathologic response; complete axillary lymph node dissection (ALND) after neoadjuvant chemotherapy is recommended in the following situations: * Patients had documented pathologic involvement of the axillary nodes (fine needle aspiration [FNA] or core biopsy) before neoadjuvant chemotherapy and had sentinel node biopsy after neoadjuvant chemotherapy with positive sentinel node(s) * Patient had documented pathologic involvement of the axillary nodes (FNA or core biopsy) before neoadjuvant chemotherapy and had only 1 sentinel lymph node removed after neoadjuvant chemotherapy ** Except for (i) patients participating in the Alliance A11202 trial) or (ii) if the treating surgeon determines that a complete ALND is not in the best interest of the patient ** NOTE: Patients who undergo sentinel node biopsy before starting neoadjuvant treatment and do not undergo post neoadjuvant assessment of the axillary nodes or who have negative axillary nodes on post neoadjuvant assessment must have >= 1 cm residual invasive cancer in the breast after completion of neoadjuvant chemotherapy
- Patients must have a minimum of five, available unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) from the residual (post-neoadjuvant) invasive tumor in primary site or lymph node; (these will be submitted to a central laboratory to determine PD-L1 expression); the tumor tissue must be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells per slide; local PD-L1 results, even if available, will not substitute for central testing * NOTE: Initial order for specimen kits should be placed at least two weeks prior to registering the first patient at each site
- Patients must be offered the opportunity to participate in specimen banking
- The BAHO substudy was permanently closed to accrual on June 23, 2020, and willingness of English-speaking patients to participate in the BAHO substudy is no longer applicable
- Patients must have had neoadjuvant chemotherapy followed by surgery; the choice of neoadjuvant chemotherapy is determined by the treating physician; we recommend following the National Comprehensive Cancer Network (NCCN) treatment guidelines for TNBC; patients who cannot complete all planned treatment cycles for any reason are considered high risk and therefore are eligible for the study if they have residual disease; patients must have resolution of adverse event(s) of the most recent prior chemotherapy to grade 1 or less, except alopecia and =< grade 2 neuropathy which are allowed
- Patients may receive post-operative (adjuvant) chemotherapy for up to 24 weeks of duration (e.g. 8 cycles of capecitabine as in the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) trial; the 24-week duration does not include treatment delays) after completion of surgery at the discretion of the treating physician; co-enrollment to EA1131 is allowed, provided that patients complete or discontinue adjuvant chemotherapy prior to step 1 registration; at the time of step 1 registration, patients must have resolution of adverse event(s) of the most recent prior chemotherapy to =< grade 1, except alopecia and =< grade 2 neuropathy which are allowed; patients that have received adjuvant chemotherapy (including via co-enrollment to EA1131) must be registered to step 1 within 35 days after final dose of adjuvant chemotherapy
- Patients must have completed their final breast surgery (rendering them free from disease) with clear resection margins for invasive cancer and DCIS within the following timelines: * 90 days prior to step 1 screening registration for patients not receiving post-operative (adjuvant) chemotherapy OR * 270 days prior to step 1 screening registration for patients who have received post-operative (adjuvant) chemotherapy Positive margins are allowed only if the surgical team of the patient deems further resection impossible
- Patients for whom radiation therapy (RT) to the affected breast or chest wall and regional nodal areas is clinically indicated as per NCCN treatment guidelines, should receive routine RT after randomization when possible, and receive MK-3475 (pembrolizumab) concurrent with RT, if randomized to the experimental arm; however, routine RT administered, or initiated, prior to registration is also allowed; MK-3475 (pembrolizumab) may be added to ongoing radiation, or started after its completion, if randomized to the experimental arm, provided there are no > grade 1 radiation-related skin toxicities and provided that no radiosensitizing chemotherapy is being administered; co-enrollment in the Alliance A221505 (NCT03414970) and A011202 (NCT01901094) trials or in the NSABP-B51 (NCT01872975) trial is allowed, but patients must not be planning to receive radiation therapy given on these trials concurrently with MK-3475 (pembrolizumab) treatment on S1418/BR006; whether or not patient will receive RT and the extent of intended RT must be specified at time of registration; NOTE: Patients who receive post-operative chemotherapy may receive radiation therapy before or after the chemotherapy; a short course of reduced dose chemotherapy or other agents concomitant with radiation for radiation sensitization is not considered to be adjuvant chemotherapy
- Patients must not have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs; patients must not be planning to receive any of the prohibited therapies during the screening or treatment phases of the study
- Patients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol; however, patients receiving extended adjuvant endocrine therapy for an earlier ER positive breast cancer treated with curative intent and without recurrence for at least 5 years may continue with their endocrine therapy; elective surgery or surgery that is not related to cancer therapy is allowed, at the discretion of the treating investigator
- Patients must have Zubrod performance status =< 2
- Patients must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within 2 years prior to registration
- Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- Patients must not have received live vaccines within 30 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
- Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria: * CD4 counts >= 350 mm^3 * Serum HIV viral load of < 25,000 IU/ml and * Treated on a stable antiretroviral regimen
- No other prior invasive malignancy is allowed except for the following: adequately treated basal (or squamous cell) skin cancer, in situ breast or cervical cancer; stage I or II invasive cancer treated with a curative intent without evidence of disease recurrence for at least five years
- Patients must have complete history and physical examination within 28 days prior to registration
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- STEP 2 REGISTRATION
- Patients must not be registered to step 2 until receiving confirmation from the Southwest Oncology Group (SWOG) Statistical and Data Management Center that the patient's tissue specimen was adequate for PD-L1 testing; patients must be registered within 14 days of receiving the e-mail notification confirming submission was evaluable for PD-L1 status
- Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (obtained within 28 days prior to step 2 registration)
- Platelets >= 100,000/mcL (obtained within 28 days prior to step 2 registration)
- Hemoglobin >= 9 g/dL (obtained within 28 days prior to step 2 registration)
- A serum thyroid-stimulating hormone (TSH) and/or free T4 must be obtained within 28 days prior to step 2 registration to obtain a baseline value
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert’s syndrome, who must have a total bilirubin < 3.0 mg/dL) (obtained within 28 days prior to step 2 registration)
- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x IULN (obtained within 28 days prior to step 2 registration)
- Alkaline phosphatase =< 2.5 x IULN (obtained within 28 days prior to step 2 registration)
- Serum creatinine =< IULN OR measured or calculated creatinine clearance >= 60 mL/min (obtained within 28 days prior to step 2 registration)
- Women of childbearing potential must have a negative urine or serum pregnancy test within 28 day prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or vasectomy; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures; patients must not be pregnant or nursing; women of childbearing potential must plan to have a urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be required
- Patients must not have an active infection requiring systemic therapy at the time of starting therapy
- Site must verify that there is no known change in the step 1 eligibility since initial registration
Alabama
Birmingham
Daphne
Mobile
Alaska
Anchorage
Fairbanks
Arizona
Gilbert
Goodyear
Tucson
Arkansas
Jonesboro
Little Rock
Rogers
California
Anaheim
Antioch
Arroyo Grande
Auburn
Bakersfield
Baldwin Park
Bellflower
Berkeley
Burlingame
Clovis
Corona
Costa Mesa
Duarte
Dublin
Emeryville
Fontana
Fremont
Fresno
Fullerton
Greenbrae
Harbor City
Irvine
Loma Linda
Los Angeles
Martinez
Marysville
Mission Hills
Modesto
Monterey
Mountain View
Newport Beach
Novato
Oakland
Ontario
Orange
Palm Springs
Palo Alto
Panorama City
Pasadena
Redwood City
Richmond
Riverside
Roseville
Sacramento
Salinas
San Diego
San Francisco
San Jose
San Leandro
San Luis Obispo
San Marcos
Santa Clara
Santa Cruz
Santa Maria
Santa Rosa
South Pasadena
South San Francisco
Stockton
Sunnyvale
Truckee
Upland
Vacaville
Vallejo
Walnut Creek
Whittier
Woodland Hills
Colorado
Aurora
Boulder
Colorado Springs
Denver
Englewood
Fort Collins
Golden
Grand Junction
Greeley
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Thornton
Wheat Ridge
Connecticut
Danbury
Derby
Fairfield
Greenwich
Hartford
Meriden
New Britain
New Haven
North Haven
Norwalk
Orange
Torrington
Trumbull
Waterbury
Delaware
Frankford
Newark
Rehoboth Beach
Seaford
District of Columbia
Washington
Florida
Altamonte Springs
Celebration
Clearwater
Coral Gables
Daytona Beach
Deerfield Beach
Gainesville
Jacksonville
Miami
Miami Beach
Orlando
Pensacola
Plantation
Tallahassee
Tampa
Weston
Georgia
Albany
Atlanta
Augusta
Decatur
Duluth
Lawrenceville
Newnan
Savannah
Snellville
Valdosta
Hawaii
Aiea
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Arlington Heights
Aurora
Berwyn
Bloomington
Canton
Carterville
Carthage
Centralia
Chicago
Danville
DeKalb
Decatur
Effingham
Eureka
Evanston
Freeport
Galesburg
Geneva
Glenview
Harvey
Highland Park
Joliet
Kankakee
Kewanee
Lake Forest
Macomb
Mattoon
Maywood
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
River Forest
Rockford
Silvis
Springfield
Urbana
Warrenville
Yorkville
Indiana
Carmel
Evansville
Fort Wayne
Goshen
Indianapolis
Kokomo
Lafayette
Mishawaka
New Albany
Newburgh
South Bend
Terre Haute
Iowa
Ames
Bettendorf
Boone
Cedar Rapids
Clive
Creston
Davenport
Des Moines
Fort Dodge
Iowa City
Jefferson
Marshalltown
West Des Moines
Kansas
Chanute
Dodge City
Fort Scott
Garden City
Great Bend
Hays
Kansas City
Kingman
Lawrence
Lenexa
Liberal
McPherson
Newton
Olathe
Overland Park
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Louisiana
Alexandria
Baton Rouge
Covington
Houma
Kenner
Lake Charles
Metairie
New Orleans
Shreveport
Maine
Augusta
Bangor
Belfast
Biddeford
Brewer
Kennebunk
Norway
Rockport
Sanford
Scarborough
South Portland
Topsham
York
Maryland
Annapolis
Baltimore
Bel Air
Frederick
Ocean Pines
Salisbury
Towson
Massachusetts
Boston
Burlington
Lowell
Springfield
Winchester
Michigan
Ann Arbor
Battle Creek
Bay City
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
East Lansing
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Kalamazoo
Lansing
Lapeer
Livonia
Macomb Township
Marlette
Marquette
Midland
Monroe
Mount Clemens
Mount Pleasant
Muskegon
Novi
Petoskey
Pontiac
Port Huron
Reed City
Rochester Hills
Royal Oak
Saginaw
Saint Joseph
Southfield
Traverse City
Troy
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Bemidji
Brainerd
Burnsville
Coon Rapids
Deer River
Duluth
Edina
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
New Ulm
Robbinsdale
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Virginia
Waconia
Willmar
Woodbury
Wyoming
Mississippi
Columbus
Grenada
New Albany
Oxford
Pascagoula
Southhaven
Missouri
Ballwin
Bolivar
Cape Girardeau
Independence
Jefferson City
Joplin
Kansas City
North Kansas City
Saint Joseph
Saint Louis
Springfield
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Omaha
Nevada
Henderson
Las Vegas
Reno
New Hampshire
Concord
Lebanon
Manchester
Nashua
New Jersey
Brick
Elizabeth
Hackensack
Hamilton
Livingston
Long Branch
Manahawkin
Mount Holly
Neptune
New Brunswick
Newark
Paramus
Red Bank
Ridgewood
Somerville
Sparta
Voorhees
Westwood
New Mexico
Albuquerque
Las Cruces
Rio Rancho
Santa Fe
New York
Bronx
Brooklyn
Buffalo
Elmira
Middletown
Mineola
New York
Rochester
Staten Island
Stony Brook
Syracuse
White Plains
North Carolina
Albemarle
Asheboro
Asheville
Burlington
Chapel Hill
Charlotte
Clinton
Concord
Durham
Goldsboro
Greensboro
Hendersonville
Huntersville
Jacksonville
Kenansville
Kernersville
Kinston
Matthews
Mebane
Mooresville
Mount Airy
Pinehurst
Reidsville
Richlands
Stateville
Thomasville
Wilkesboro
Winston-Salem
North Dakota
Bismarck
Fargo
Ohio
Akron
Beachwood
Beavercreek
Belpre
Canton
Centerville
Chardon
Chillicothe
Cincinnati
Cleveland
Columbus
Delaware
Elyria
Franklin
Independence
Kettering
Lima
Mansfield
Marietta
Marion
Mayfield Heights
Mentor
Middleburg Heights
Mount Vernon
Newark
Parma
Perrysburg
Portsmouth
Sandusky
Springfield
Steubenville
Strongsville
Sylvania
Toledo
Wadsworth
Warrensville Heights
Westerville
Westlake
Wooster
Zanesville
Oklahoma
Lawton
Oklahoma City
Tulsa
Oregon
Baker City
Clackamas
Corvallis
Grants Pass
Gresham
Medford
Newberg
Ontario
Portland
Tualatin
Pennsylvania
Abington
Allentown
Bethlehem
Bryn Mawr
Doylestown
Erie
Harrisburg
Jefferson Hills
Media
Monroeville
Paoli
Philadelphia
Pittsburgh
West Chester
West Reading
Wexford
Williamsport
Willow Grove
Wynnewood
York
Puerto Rico
Bayamon
Manati
San Juan
South Carolina
Anderson
Bluffton
Boiling Springs
Charleston
Clinton
Easley
Florence
Gaffney
Georgetown
Greenville
Greenwood
Greer
Hilton Head Island
Rock Hill
Seneca
Spartanburg
Union
West Columbia
South Dakota
Pierre
Rapid City
Sioux Falls
Tennessee
Collierville
Franklin
Kingsport
Knoxville
Lenoir City
Maryville
Memphis
Nashville
Oak Ridge
Texas
Amarillo
Austin
Baytown
Conroe
Houston
League City
Nassau Bay
Sugar Land
The Woodlands
Utah
Farmington
Salt Lake City
South Jordan
Vermont
Saint Johnsbury
Virginia
Bristol
Fairfax
Fishersville
Gloucester
Lynchburg
Mechanicsville
Midlothian
Newport News
Norton
Richmond
South Hill
Virginia Beach
Williamsburg
Winchester
Washington
Aberdeen
Bellevue
Bellingham
Bremerton
Centralia
Edmonds
Kennewick
Kirkland
Lacey
Longview
Mount Vernon
Port Townsend
Poulsbo
Seattle
Spokane
Vancouver
Yakima
West Virginia
Huntington
Wisconsin
Antigo
Appleton
Ashland
Brookfield
Burlington
Chilton
Fond Du Lac
Franklin
Germantown
Grafton
Green Bay
Johnson Creek
Kenosha
La Crosse
Madison
Marinette
Medford
Mequon
Milwaukee
Mukwonago
New Richmond
Oconomowoc
Oconto Falls
Oshkosh
Racine
Sheboygan
Stevens Point
Sturgeon Bay
Summit
Two Rivers
Waukesha
Waupaca
Wausau
Wauwatosa
West Allis
Wisconsin Rapids
Wyoming
Cody
Alberta
Calgary
Edmonton
British Columbia
Surrey
Vancouver
New Brunswick
Moncton
Saint John
Newfoundland
St. John's
Ontario
Hamilton
Kitchener
London
Newmarket
Sault Ste Marie
Toronto
Quebec
Laval
Montreal
Quebec City
Saskatchewan
Regina
PRIMARY OBJECTIVE:
I. To compare invasive disease-free survival (IDFS) of patients with triple-negative (TNBC) or low estrogen receptor (ER)-positive and/or HER2 borderline breast cancer who have >= 1 cm residual invasive breast cancer and/or positive lymph nodes (ypN1mi, ypN1, ypN2, ypN3) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset.
SECONDARY OBJECTIVES:
I. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive patients and then all patients.
II. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient population with or without radiation therapy.
BEHAVIORAL AND HEALTH OUTCOMES (BAHO) STUDY OBJECTIVES:
I. To examine the association between biomarkers of inflammation and quality of life and patient reported outcomes between the two groups during and at the end of therapy.
II. To examine the long-term and late effects of treatment on patient-reported outcomes.
ADDITIONAL OBJECTIVE:
I. To collect tissue and whole blood for processing and banking in anticipation of future correlative studies in this patient population.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I (OBSERVATION): Patients receive no treatment but are monitored at standard clinical intervals during first year after randomization. Patients are examined every 12 weeks for 1 year, and every 6 months for 4 years, then annually for 5 years.
ARM II (PEMBROLIZUMAB): Patients receive pembrolizumab intravenously (IV) over 30 minutes on days 1 and 22. Cycles repeat every 42 days for 52 weeks in the absence of disease progression or unacceptable toxicity.
All patients may undergo radiation therapy within 12 weeks of last breast cancer operation or after treatment.
After completion of study treatment, patients are followed up every 6 months for 5 years, then annually thereafter until 10 years from treatment randomization.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
SWOG
Principal Investigator
Lajos Pusztai
- Primary ID S1418
- Secondary IDs NCI-2016-01595, S1418/BR006, s16-02231
- Clinicaltrials.gov ID NCT02954874